

CHAPTER ONE: INTRODUCTION.....	1
REASONS FOR DOING THE STUDY	1
STUDY GOALS AND OBJECTIVES.....	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	2
METHODOLOGIES AND INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	2
RELATED REPORTS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL MARKET FOR AUTOIMMUNE</i>	
<i>TREATMENTS, THROUGH 2016 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE GLOBAL MARKET FOR AUTOIMMUNE</i>	
<i>TREATMENTS BY GEOGRAPHICAL AREA, 2011 AND 2016 (%)</i>	5
<i>SUMMARY FIGURE (CONTINUED)</i>	6
 CHAPTER THREE: OVERVIEW OF AUTOIMMUNE DISEASE	 7
AUTOIMMUNITY AND THE AUTOIMMUNE SYSTEM.....	7
COMPLEX HUMAN IMMUNE SYSTEM	7
INNATE IMMUNE SYSTEM.....	7
ADAPTIVE IMMUNE SYSTEM	8
GENETICS AND AUTOIMMUNE DISEASES.....	8
NEW GENETIC RESEARCH.....	9
ROLES OF T CELLS, B CELLS, PHAGOCYTES, AND	
GRANULOCYTES	9
T Cells	10
B Cells	10
Phagocytes and Granulocytes	11
ROLE OF HUMAN LEUKOCYTE ANTIGEN	11
ROLE OF CYTOKINES.....	11
ROLES OF ANTIBODIES	12
CAUSES OF AUTOIMMUNE DISEASES.....	12
WOMEN AND AUTOIMMUNE DISEASE	12
GENETIC DIFFERENCE IN AUTOIMMUNE DISEASES	13
AFFECTS ON ETHNIC GROUPS	13
ROLE OF THE ENVIRONMENT	14
<i>TABLE 1 INFECTIONS IN HUMANS ASSOCIATED WITH SELECTED</i>	
<i>AUTOIMMUNE DISEASES</i>	14
DIAGNOSING AUTOIMMUNE DISEASES.....	14
SYSTEMIC AND LOCALIZED DISEASES.....	15
MAJOR RECOGNIZED AUTOIMMUNE DISEASES	15

<i>TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT, 2011</i>	16
CHAPTER FOUR: MARKET FOR AUTOIMMUNE PHARMACEUTICALS	17
<i>TABLE 3 GLOBAL MARKET FOR PHARMACEUTICAL THERAPIES FOR LEADING AUTOIMMUNE DISEASES, THROUGH 2016 (\$ MILLIONS)</i>	17
RHEUMATOID ARTHRITIS	17
DEFINITION.....	17
SYMPTOMS AND DIAGNOSIS	18
TREATMENT	18
Treatment (Continued).....	19
<i>TABLE 4 AMERICAN COLLEGE OF RHEUMATOLOGY RECOMMENDATIONS FOR RA TREATMENTS, 2008</i>	20
<i>TABLE 5 GLOBAL MARKET FOR RHEUMATOID ARTHRITIS MEDICATIONS, THROUGH 2016 (\$ MILLIONS)</i>	21
TYPE 1 DIABETES.....	21
Definition	21
Scope	22
Symptoms and Diagnosis	22
Treatment	23
<i>TABLE 6 GLOBAL MARKET FOR TYPE 1 DIABETES PHARMACEUTICAL PRODUCTS, THROUGH 2016 (\$ MILLIONS)</i>	24
<i>TABLE 7 MAJOR MANUFACTURERS OF DIABETES PRODUCTS, 2011</i>	24
<i>FIGURE 1 GLOBAL MARKET SHARE FOR TYPE 1 DIABETES INSULIN PRODUCTS BY MANUFACTURER, 2011 (%)</i>	25
LUPUS.....	25
Definition	25
Systemic Lupus Erythematosus.....	26
Cutaneous Lupus Erythematosus.....	26
Drug-induced and Neonatal Lupus Erythematosus.....	26
Scope	27
Treatment	27
New Approval	27
<i>TABLE 8 PHARMACEUTICAL TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY CONDITION TYPE, 2011</i>	28
<i>TABLE 9 INVESTIGATIONAL TREATMENTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS, 2011</i>	28
<i>TABLE 9 (CONTINUED)</i>	29
<i>TABLE 10 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT LUPUS, THROUGH 2016 (\$ MILLIONS)</i>	30
MULTIPLE SCLEROSIS.....	30
Definition	30
Scope	30

Symptoms and Diagnosis	31
Treatment	31
<i>TABLE 11 PHARMACOLOGICAL TREATMENTS FOR MULTIPLE SCLEROSIS BY NAME, MANUFACTURER, DOSAGE, AND APPROVAL DATE, 2011</i>	<i>32</i>
<i>TABLE 12 MARKET FOR MS PHARMACEUTICALS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>33</i>
INFLAMMATORY BOWEL DISEASE	33
<i>TABLE 13 GLOBAL MARKET FOR IBD MEDICATIONS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>33</i>
Ulcerative Colitis.....	34
Definition.....	34
Scope.....	34
Symptoms and Diagnosis	34
Treatment.....	34
<i>TABLE 14 MEDICATIONS TO TREAT ULCERATIVE COLITIS, 2011</i>	<i>35</i>
<i>TABLE 15 GLOBAL MARKET FOR MEDICATIONS TO TREAT ULCERATIVE COLITIS, THROUGH 2016 (\$ MILLIONS)</i>	<i>35</i>
Crohn's Disease	36
Definition.....	36
Scope.....	36
Symptoms and Diagnosis	36
Treatment.....	36
<i>TABLE 16 CURRENT MEDICATIONS FOR THE TREATMENT OF CROHN'S DISEASE BY MANUFACTURER, 2011</i>	<i>37</i>
<i>TABLE 17 GLOBAL MARKET FOR MEDICATIONS TO TREAT CROHN'S DISEASE, THROUGH 2016 (\$ MILLIONS).....</i>	<i>38</i>
PSORIASIS.....	38
Definition	38
Symptoms and Diagnosis	38
Treatment	39
<i>TABLE 18 SELECTED CURRENT MEDICATIONS FOR PSORIASIS, 2011</i>	<i>39</i>
<i>TABLE 18 (CONTINUED).....</i>	<i>40</i>
<i>TABLE 19 GLOBAL MARKET FOR PSORIASIS PHARMACEUTICALS, THROUGH, 2016 (\$ MILLIONS).....</i>	<i>40</i>
OTHER MAJOR AUTOIMMUNE DISEASES.....	40
SCLERODERMA.....	41
Scope	41
Symptoms and Diagnosis	41
Treatment	41
ANKYLOSING SPONDYLITIS.....	42
Definition	42
Symptoms and Diagnosis	42

Treatment	42
GRAVES' DISEASE	43
Definition	43
Scope	43
Symptoms and Diagnosis	43
Treatment	44
CELIAC DISEASE	44
Definition	44
Scope	44
Symptoms and Diagnosis	45
Treatment	46
SJÖGREN'S SYNDROME	46
Definition	46
Scope	46
Signs and Symptoms	46
Treatment	47
RECOGNIZED AUTOIMMUNE AND AUTOIMMUNE-RELATED DISEASES	47
<i>TABLE 20 RECOGNIZED AUTOIMMUNE AND AUTOIMMUNE- RELATED DISEASES*</i>	47
<i>TABLE 20 (CONTINUED)</i>	48
<i>TABLE 20 (CONTINUED)</i>	49
CHAPTER FIVE: GLOBAL AUTOIMMUNE PHARMACEUTICAL THERAPIES MARKET.....	50
<i>TABLE 21 GLOBAL AUTOIMMUNE PHARMACEUTICAL THERAPY MARKET BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	50
REGIONAL VARIATIONS.....	50
RA AND MS PREVALENCE BY GEOGRAPHIC REGIONS	51
<i>TABLE 22 TOP 10 COUNTRIES IN WHICH MS IS MOST OR LEAST PREVALENT (PREVALENCE PER 100,00)</i>	52
DRIVERS OF AUTOIMMUNE TREATMENT MARKET	52
<i>FIGURE 2 GLOBAL MARKET SHARE FOR AUTOIMMUNE THERAPIES BY REGION, 2011 AND 2016 (%)</i>	53
U.S. MARKET	54
SCOPE	54
Celiac Disease in the U.S.	54
Pharmaceuticals	54
Other Therapies.....	54
<i>TABLE 23 U.S. MARKET FOR U.S. AUTOIMMUNE PHARMACEUTICAL THERAPIES, THROUGH 2016 (\$ MILLIONS)</i>	55
EUROPEAN MARKET.....	55
SCOPE	55
Type 1 Diabetes	55
Pharmaceuticals	56

<i>TABLE 24 EUROPEAN MARKET FOR AUTOIMMUNE PHARMACEUTICALS, THROUGH 2016 (\$ MILLIONS)</i>	56
JAPANESE MARKET	56
SCOPE	56
RA in Japan	57
Type 1 Diabetes in Japan	57
MS in Japan	57
Pharmaceuticals	58
<i>TABLE 25 APPROVED DMARDS AND BIOLOGICALS FOR TREATMENT OF RA IN JAPAN AND THE U.S., 2009</i>	58
<i>TABLE 26 JAPANESE MARKET FOR AUTOIMMUNE PHARMACEUTICALS, THROUGH 2016 (\$ MILLIONS)</i>	59
REST OF THE WORLD MARKET	59
SCOPE	59
Diabetes	59
<i>TABLE 27 REST OF THE WORLD MARKET FOR AUTOIMMUNE PHARMACEUTICALS, THROUGH 2016 (\$ MILLIONS)</i>	60
AFFECTS OF HEALTHCARE REFORM	60
U.S.	60
HEALTHCARE REFORM OUTSIDE THE U.S.	61
EMERGING TRENDS IN TREATMENTS	61
TYPE 1 DIABETES	61
CHANGES IN THE INDUSTRY	62
<i>TABLE 28 SELECTED MERGERS AND/OR ACQUISITIONS, 2006–2011 (\$ MILLIONS)</i>	62
 CHAPTER SIX: AUTOIMMUNE DISEASE PHARMACEUTICAL MARKET	
BY PHARMACEUTICAL TYPE	63
TYPES OF APPROPRIATE PHARMACEUTICALS	63
<i>TABLE 29 GLOBAL MARKET FOR AUTOIMMUNE PHARMACEUTICALS BY TYPE, THROUGH 2016 (\$ MILLIONS)</i>	63
<i>FIGURE 3 GLOBAL MARKET SHARE FOR AUTOIMMUNE PHARMACEUTICALS BY TYPE, 2011 AND 2016 (%)</i>	64
<i>FIGURE 3 (CONTINUED)</i>	65
TUMOR NECROSIS FACTOR INHIBITORS	65
<i>TABLE 30 TNF INHIBITORS AVAILABLE IN THE U.S., E.U., AND JAPAN, 2011</i>	66
METHOD OF ACTION	66
<i>FIGURE 4 GLOBAL MARKET SHARE FOR TNF PHARMACEUTICAL MARKET BY PRODUCT, 2011 (%)</i>	66
<i>FIGURE 4 (CONTINUED)</i>	67
ADVERSE EFFECTS	67
<i>TABLE 31 TNF INHIBITORS FOR AUTOIMMUNE DISEASES, 2011</i>	68
<i>TABLE 32 GLOBAL MARKET FOR TNF INHIBITORS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2016 (\$ MILLIONS)</i>	68

B-CELL INHIBITORS.....	69
METHOD OF ACTION	69
ADVERSE EFFECTS.....	69
T-CELL INHIBITORS	70
METHOD OF ACTION	70
ADVERSE EFFECTS.....	70
<i>TABLE 33 B-CELL AND T-CELL INHIBITORS FOR AUTOIMMUNE</i>	
<i>DISEASES, 2011</i>	<i>71</i>
<i>TABLE 34 GLOBAL MARKET FOR B-CELL AND T-CELL</i>	
<i>INHIBITORS, THROUGH 2016 (\$ MILLIONS)</i>	<i>71</i>
INTERLEUKIN INHIBITORS.....	71
METHOD OF ACTION	72
ADVERSE EFFECTS.....	72
CURRENT TREATMENTS	72
<i>TABLE 35 INTERLEUKIN INHIBITORS FOR AUTOIMMUNE</i>	
<i>DISEASES, 2011</i>	<i>72</i>
MARKET FOR INTERLEUKIN INHIBITORS	73
<i>TABLE 36 MARKET FOR INTERLEUKIN PRODUCTS TO TREAT</i>	
<i>AUTOIMMUNE DISEASES, THROUGH 2016 (\$ MILLIONS)</i>	<i>73</i>
IMMUNOSUPPRESSANTS	73
<i>TABLE 37 IMMUNOSUPPRESSANTS FOR AUTOIMMUNE</i>	
<i>DISEASES, 2011</i>	<i>74</i>
METHOD OF ACTION	74
Antimetabolites	74
Antimetabolites Used in the Treatment of Type 1	
Diabetes	75
Calcineurin Inhibitors	75
Anticytokines	75
ADVERSE EFFECTS.....	75
<i>TABLE 38 GLOBAL MARKET FOR IMMUNOSUPPRESSANTS TO</i>	
<i>TREAT AUTOIMMUNE DISEASES, THROUGH 2016 (\$ MILLIONS).....</i>	<i>76</i>
BETA INTERFERONS	76
METHOD OF ACTION	76
ADVERSE EFFECTS.....	77
<i>TABLE 39 BETA INTERFERONS FOR AUTOIMMUNE DISEASES,</i>	
<i>2011</i>	<i>77</i>
<i>TABLE 40 GLOBAL MARKET FOR BETA INTERFERONS, THROUGH</i>	
<i>2016 (\$ MILLIONS).....</i>	<i>77</i>
INSULIN	78
<i>TABLE 41 GLOBAL MARKET FOR INSULIN, THROUGH 2016 (\$</i>	
<i>MILLIONS).....</i>	<i>78</i>
OTHER DRUGS AND THERAPIES WITH DIFFERING METHODS	
OF ACTION	78
COX II INHIBITORS	78

SPHINGOSINE KINASE	79
LEFLUNOMIDE	79
GLATIRAMER	79
INTRAVENOUS IMMUNOGLOBULIN.....	79
PLASMAPHERESIS	80
HORMONE REPLACEMENT THERAPY.....	80
ENZYME REPLACEMENT THERAPY.....	80
<i>TABLE 42 OTHER PHARMACEUTICAL PRODUCTS WITH DIFFERING MECHANISMS OF ACTION TO TREAT AUTOIMMUNE DISEASES, 2011</i>	<i>81</i>
<i>TABLE 43 MARKET FOR OTHER DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2016 (\$ MILLIONS)</i>	<i>82</i>
OTHER MECHANISMS OF ACTION.....	82
SPLEEN TYROSINE KINASE INHIBITORS.....	82
PATENT EXPIRATIONS	82
<i>TABLE 44 PATENT EXPIRIES FOR PHARMACEUTICALS TO TREAT AUTOIMMUNE DISEASES, 2007–2018</i>	<i>83</i>
NEW DRUG APPROVALS IN 2009 AND 2010	83
<i>TABLE 45 NEW DRUG APPROVALS FOR TREATMENT OF AUTOIMMUNE DISEASES, 2009–2011</i>	<i>83</i>
CHAPTER SEVEN: AUTOIMMUNE DIAGNOSTIC TESTING MARKET.....	84
ENZYME-LINKED IMMUNOSORBENT ASSAY	84
IMMUNOFLUORESCENCE ASSAY	84
HLA TESTING.....	85
MANUAL TESTING METHODS.....	85
AUTOMATED TESTING METHODS	86
<i>TABLE 46 LEADING MANUFACTURERS OF AUTOMATED DIAGNOSTIC TESTING EQUIPMENT.....</i>	<i>86</i>
CURRENT DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASE.....	86
<i>TABLE 47 SELECTED MANUFACTURERS OF DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASES, 2011</i>	<i>87</i>
SYSTEMIC AUTOIMMUNE DIAGNOSTIC TESTS	88
Antinuclear Antibodies.....	88
Anti-Neutrophil Cytoplasmic	88
Anti-Double-Stranded DNA	89
Extractable Nuclear Antigen Antibodies Panel	89
Rheumatoid Factor	89
Cyclic Citrullinated Peptide Antibody.....	90
LOCALIZED AUTOIMMUNE DIAGNOSTIC TESTS	90
Liver	90
Kidney	90
Thyroid.....	90
Gastrointestinal Tract.....	91
<i>TABLE 48 TEST TYPE BY AUTOIMMUNE CONDITION, 2011</i>	<i>91</i>

MARKET FOR DIAGNOSTIC TESTS FOR AUTOIMMUNE DISEASE	91
<i>TABLE 49 GLOBAL MARKET FOR AUTOIMMUNE DIAGNOSTIC TESTS, THROUGH 2016 (\$ MILLIONS)</i>	<i>92</i>

CHAPTER EIGHT: AUTOIMMUNE TREATMENT ASSISTIVE

TECHNOLOGIES	93
AUTOIMMUNE THERAPIES	93
NUTRITION	93
Affect of Vitamins	93
Vitamin D and MS.....	94
Beta-cell Autoimmunity in Children	94
EXERCISE.....	95
STRESS REDUCTION	95
PHARMACEUTICAL MANAGEMENT.....	96
ASSISTIVE PRODUCTS	96
<i>TABLE 50 GLOBAL MARKET FOR ASSISTIVE TECHNOLOGIES TO TREAT TYPE 1 DIABETES, THROUGH 2016 (\$ MILLIONS)</i>	<i>96</i>
<i>FIGURE 5 GLOBAL MARKET SHARE FOR BLOOD GLUCOSE MONITORS TO TREAT TYPE 1 DIABETES BY MANUFACTURER, 2011 (%)</i>	<i>97</i>

CHAPTER NINE: CURRENT RESEARCH AND EMERGING

PHARMACEUTICALS.....	98
THERAPEUTIC VACCINES	98
STATINS	98
PHARMACEUTICALS	99
ANTARES PHARMA, INC.	99
RA99	
ARGENTIS	99
Systemic Scleroderma	99
RA100	
BIOGEN IDEC	100
Dalfampridine.....	100
BG-12	100
Daclizumab	100
Pegylated Interferon Beta-1a.....	101
Dexpramipexole	101
ELI LILLY	101
BAFF Antibody	101
Bl10773 and Linagliptin.....	101
GENZYME/BAYER.....	102
GLAXOSMITHKLINE	102
Otelixizumab.....	102
Horizant	103
CCX282	103

GSK2402968	103
IMMUNOMEDICS/UCB PHARMACEUTICALS	103
SLE	103
MERCK	103
NATIONAL INSTITUTES OF HEALTH	104
NOVO NORDISK	104
PFIZER	104
Halofuginone	105
SANOFI-AVENTIS	105
Teriflunomide	105
SAR143091	105
SAR288223	106
TEVA PHARMACEUTICAL	106
Laquinimod	106
DIAGNOSTIC TESTING	107
CHAPTER TEN: REGULATIONS AND PATENTS	108
REGULATIONS	108
U.S. REGULATIONS	108
Pharmaceuticals	108
EUROPEAN REGULATIONS	108
Pharmaceuticals	108
JAPANESE REGULATIONS	109
Pharmaceuticals	109
REST OF THE WORLD REGULATIONS	109
Pharmaceuticals	109
PATENTS	110
PATENTS BY MANUFACTURER	110
<i>TABLE 51 PATENTS BY MANUFACTURER</i>	110
PATENTS BY DATE OF ISSUE	110
<i>TABLE 52 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2009–</i>	
<i>2011</i>	111
PATENTS BY MANUFACTURER	111
<i>TABLE 53 PATENTS BY MANUFACTURER</i>	111
<i>TABLE 53 (CONTINUED)</i>	112
COMPOUND PATENTS FOR AUTOIMMUNE APPLICATIONS ...	112
<i>TABLE 54 PATENT COMPOUNDS FOR AUTOIMMUNE</i>	
<i>TREATMENTS, 2005–2011</i>	112
<i>TABLE 54 (CONTINUED)</i>	113
<i>TABLE 54 (CONTINUED)</i>	114
PATENTS BY INDICATION	114
<i>TABLE 55 PATENTS BY INDICATION: RHEUMATOID ARTHRITIS,</i>	
<i>2005–2011</i>	115
<i>TABLE 56 PATENTS BY INDICATION: INFLAMMATORY BOWEL</i>	
<i>DISEASES, 2005–2011</i>	115

<i>TABLE 57 PATENTS BY INDICATION: TYPE 1 DIABETES, 2005–2011.....</i>	<i>116</i>
PATENTS FOR AUTOIMMUNE DISEASE TESTING	116
<i>TABLE 58 PATENT BY INDICATION: DIAGNOSTIC TESTING AND</i>	
<i>ASSAYS, 2005–2011</i>	<i>116</i>

CHAPTER ELEVEN: COMPANY DIRECTORY	117
PHARMACEUTICAL COMPANIES.....	117
ABBOTT LABORATORIES	117
Business Overview	117
Financials.....	117
Products	117
AMGEN	118
Business Overview	118
Financials.....	118
Products	118
ASTELLAS PHARMA, INC.....	119
Business Overview	119
Financial Information	119
Products	119
BAYER AG (MILES-BAYER)	120
Business Overview	120
Financials.....	120
Products	120
BIOGEN IDEC	121
Business Overview	121
Financials.....	121
Products	121
BOEHRINGER INGELHEIM GMBH.....	121
Business Overview	122
Financials.....	122
Products	122
BRISTOL-MYERS SQUIBB	122
Business Overview	122
Financials.....	123
Products	123
ELAN CORPORATION	123
Business Overview	123
Financials.....	124
Products	124
ELI LILLY	124
Business Overview	125
Financials.....	125
Products	125
EMD SERONO, INC.	125
Business Overview	125

Financials.....	126
Products	126
GENENTECH	126
Business Overview	126
Financials.....	126
Products	126
GLAXOSMITHKLINE	126
Business Overview	127
Financials.....	127
Products	127
JANSSEN BIOTECH, INC (CENTOCOR)	127
Business Overview	127
Financials.....	128
Products	128
KING PHARMACEUTICALS.....	128
MERCK.....	128
Business Overview	128
Financials.....	129
Products	129
NOVARTIS AG.....	129
Business Overview	129
Financials.....	130
Products	130
NOVO NORDISK.....	130
Business Overview	130
Financials.....	130
Products	131
PFIZER	131
Business Overview	131
Financials.....	131
Products	132
PROCTER & GAMBLE PHARMACEUTICALS	132
ROCHE PHARMACEUTICALS	132
Business Overview	132
Financials.....	132
Products	133
SALIX PHARMACEUTICALS	133
Business Overview	134
Financials.....	134
Products	134
SANOFI AVENTIS.....	134
Business Overview	134
Financials.....	135
Products	135

SCHERING-PLOUGH	135
SHIRE PLC	135
Business Overview	135
Financials.....	135
Products	136
TEVA PHARMACEUTICAL INDUSTRIES, LTD.....	136
Business Overview	136
Financials.....	136
Products	137
UCB PHARMA	137
Business Overview	137
Financials.....	137
Products	137
WARNER CHILCOTT	137
Business Overview	138
Financials.....	138
Products	138
DIAGNOSTIC TESTING COMPANIES.....	138
ABBOTT LABORATORIES, DIAGNOSTICS DIVISION	138
Business Overview	138
Financials.....	138
Products	139
ALERE, INC.	139
Business Overview	139
Financials.....	139
Products	139
BECKMAN COULTER	140
Business Overview	140
Financials.....	140
Products	140
BECTON DICKINSON COMPANY.....	140
Business Overview	141
Financials.....	141
Products	141
BIOMERIEUX, INC.	141
Business Overview	141
Financials.....	142
Products	142
BIO-RAD LABORATORIES, INC.	142
Business Overview	142
Financials.....	142
Products	143
DIASORIN SPA.....	143
Business Overview	143

Financials.....	143
Products	143
IMMCO DIAGNOSTICS.....	144
Business Overview	144
Financials.....	144
Products	144
INOVA DIAGNOSTICS	144
Business Overview	144
Financials.....	145
Products	145
INVERNESS MEDICAL INNOVATIONS.....	145
IVAX DIAGNOSTICS, INC.	145
Business Overview	145
Financials.....	145
Products	146
LUMINEX CORPORATION.....	146
Business Overview	146
Financials.....	146
Products	146
MERIDIAN BIOSCIENCE, INC.	147
Business Overview	147
Financials.....	147
Products	147
ORTHO CLINICAL DIAGNOSTICS.....	147
Business Overview	147
Financials.....	148
Products	148
PHADIA.....	148
ROCHE DIAGNOSTICS.....	148
Business Overview	148
Financials.....	148
Products	149
SCIMEDX CORPORATION	149
Business Overview	149
Financials.....	149
Products	149
SIEMENS MEDICAL SOLUTIONS	150
Business Overview	150
Financials.....	150
Products	150
THERMO FISHER SCIENTIFIC, INC.....	150
Business Overview	150
Financials.....	151
Products	151

TRINITY BIOTECH.....	151
Business Overview	151
Financials.....	151
Products	152
ZEUS SCIENTIFIC, INC.....	152
Business Overview	152
Financials.....	152
Products	152
ASSISTIVE TECHNOLOGY COMPANIES	153
ABBOTT LABORATORIES	153
Products	153
LIFESCAN (JOHNSON & JOHNSON DIABETES CARE).....	153
Business Overview	153
Financials.....	153
Products	153
ROCHE DIAGNOSTICS (DIABETES CARE)	154
Products	154